Argos Therapeutics

^{Priced, Nasdaq: ARGS}

Developing immunotherapies for the treatment of renal cell carcinoma and HIV.

Industry: Health Care

First Day Return: 0.0%

ARGS

Developing immunotherapies for the treatment of renal cell carcinoma and HIV.

IPO News for Argos Therapeutics

US IPO Recap: Revance jumps 68% in ten-IPO week 02/10/14
Argos Therapeutics prices IPO below the range at $8, raising $45 million 02/07/14
12 US IPOs planned for the week of Feb 3 02/03/14

IPO Data
IPO Date	02/06/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$45
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.argostherapeutics.com
Headquarters	Durham, NC, United States
Founded	1997
Employees at IPO	94

IPO News for Argos Therapeutics

US IPO Recap: Revance jumps 68% in ten-IPO week 02/10/14
Argos Therapeutics prices IPO below the range at $8, raising $45 million 02/07/14
12 US IPOs planned for the week of Feb 3 02/03/14

Argos Therapeutics (ARGS) Performance